CTLA4 and non-small cell lung carcinoma: Upon careful review of all study design information, we found that 3 trials involved disease types other than NSCLC, 81 trials involved drugs beyond PD-1/PD-L1 and CTLA-4 inhibitors, 5 trials used treatment modalities such as thermotherapy, electric field therapy, acupuncture, and AI devices, 33 trials did not combine radiotherapy, 6 trials did not combine immunotherapy, 3 trials focused on quality of life observation, 15 trials aimed to evaluate biomarkers, 1 trial was related to organoid research, and 2 trials, despite having different NCT numbers, had duplicate content.